Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project.
ARON-2 study
Immunotherapy
NCT05290038
Pembrolizumab
Real-world data
Survival
Tumor response
Upper tract urothelial cancer
Journal
Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970
Informations de publication
Date de publication:
08 Jun 2024
08 Jun 2024
Historique:
received:
23
02
2024
accepted:
26
05
2024
medline:
8
6
2024
pubmed:
8
6
2024
entrez:
8
6
2024
Statut:
aheadofprint
Résumé
Upper tract urothelial carcinoma (UTUC) accounts for the 5-10% of all urothelial carcinomas (UCs). In this analysis, we reported the real-world data from the ARON-2 study (NCT05290038) on the efficacy of pembrolizumab in patients with UTUC who recurred or progressed after platinum-based chemotherapy. Medical records of patients with metastatic UTUC treated with pembrolizumab as second-line therapy were reviewed from 34 institutions in 14 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate (ORR). Univariate and multivariate analyses were used to explore the association of variables of interest with OS and PFS. 235 patients were included in our analysis. Median OS was 8.6 months (95% CI 6.6-12.1), the 1 year OS rate was 43% while the 2 years OS rate 29%. The median PFS was 5.1 months (95% CI 3.9-6.9); 46% of patients were alive at 6 months, 34% at 12 months and 25% at 24 months. According to RECIST 1.1, 18 patients (8%) experienced complete response (CR), 57 (24%) partial response (PR), 44 (19%) stable disease (SD), and 116 (49%) progressive disease (PD), with an ORR of 32%. Our study confirms the effectiveness of pembrolizumab in patients pretreated with a platinum-based combination, irrespective of their sensitivity to the first-line treatment and of their histology. In addition, we emphasized the limited benefit of the treatment with pembrolizumab in patients with hepatic metastases and poor ECOG performance status.
Identifiants
pubmed: 38850317
doi: 10.1007/s10585-024-10296-0
pii: 10.1007/s10585-024-10296-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Mohanty SK, Lobo A, Cheng L (2022) The 2022 revision of World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum Pathol S0046–8177(22):00224–00226
Califano G, Ouzaid I, Laine-Caroff P, Peyrottes A, Collà Ruvolo C, Pradère B, Elalouf V, Misrai V, Hermieu JF, Shariat SF, Xylinas E (2022) Current advances in immune checkpoint inhibition and clinical genomics in upper tract urothelial carcinoma: state of the art. Curr Oncol 29(2):687–697. https://doi.org/10.3390/curroncol29020060
doi: 10.3390/curroncol29020060
pubmed: 35200559
pmcid: 8870958
Mazzaschi G, Giudice GC, Corianò M, Campobasso D, Perrone F, Maffezzoli M, Testi I, Isella L, Maestroni U, Buti S (2023) Upper tract urinary carcinoma: a unique immuno-molecular entity and a clinical challenge in the current therapeutic scenario. Technol Cancer Res Treat. https://doi.org/10.1177/15330338231159753
doi: 10.1177/15330338231159753
pubmed: 36855829
pmcid: 9983117
Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, Lotan Y, Ye D, Fernández MI, Kikuchi E, Chade DC, Babjuk M, Grollman AP, Thalmann GN (2017) Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 35(3):379–387. https://doi.org/10.1007/s00345-016-1928-x
doi: 10.1007/s00345-016-1928-x
pubmed: 27604375
Shvero A, Hubosky SG (2022) Management of upper tract urothelial carcinoma. Curr Oncol Rep 24(5):611–619. https://doi.org/10.1007/s11912-021-01179-8
doi: 10.1007/s11912-021-01179-8
pubmed: 35212921
Freifeld Y, Krabbe LM, Clinton TN, Woldu SL, Margulis V (2018) Therapeutic strategies for upper tract urothelial carcinoma. Expert Rev Anticancer Ther 18(8):765–774. https://doi.org/10.1080/14737140.2018.1481395
doi: 10.1080/14737140.2018.1481395
pubmed: 29848133
Taylor J, Meng X, Ghandour R, Margulis V (2019) Advancements in the clinical management of upper tract urothelial carcinoma. Expert Rev Anticancer Ther 19(12):1051–1060. https://doi.org/10.1080/14737140.2019.1698295
doi: 10.1080/14737140.2019.1698295
pubmed: 31770492
Califano G, Ouzaid I, Verze P, Hermieu JF, Mirone V, Xylinas E (2021) Immune checkpoint inhibition in upper tract urothelial carcinoma. World J Urol 39(5):1357–1367. https://doi.org/10.1007/s00345-020-03502-7
doi: 10.1007/s00345-020-03502-7
pubmed: 33128595
Rizzo A, Mollica V, Santoni M, Massari F (2022) Clinicopathological features of FGFR3-mutated upper tract urothelial carcinoma: a genomic database analysis. Clin Genitourin Cancer 20(5):482–487. https://doi.org/10.1016/j.clgc.2022.06.013
doi: 10.1016/j.clgc.2022.06.013
pubmed: 35858936
Cathomas R, Lorch A, Bruins HM, Compérat EM, Cowan NC, Efstathiou JA, Fietkau R, Gakis G, Hernández V, Espinós EL, Neuzillet Y (2022) The 2021 updated european association of urology guidelines on metastatic urothelial carcinoma. Eur Urol 81(1):95–103
doi: 10.1016/j.eururo.2021.09.026
pubmed: 34742583
Powles T, Smith K, Stenzl A, Bedke J (2017) Immune checkpoint inhibition in metastatic urothelial cancer. Eur Urol 72:477–481
doi: 10.1016/j.eururo.2017.03.047
pubmed: 28413128
Rouprêt M, Seisen T, Birtle AJ, Capoun O, Compérat EM, Dominguez-Escrig JL, Gürses Andersson I, Liedberg F, Mariappan P, Hugh Mostafid A, Pradere B, van Rhijn BWG, Shariat SF, Rai BP, Soria F, Soukup V, Wood RG, Xylinas EN, Masson-Lecomte A, Gontero P (2023) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol S0302–2838(23):02652. https://doi.org/10.1016/j.eururo.2023.03.013
doi: 10.1016/j.eururo.2023.03.013
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF (2017) KEYNOTE-045 investigators pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. https://doi.org/10.1056/NEJMoa1613683
doi: 10.1056/NEJMoa1613683
pubmed: 28591526
pmcid: 5635424
Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30(6):970–976. https://doi.org/10.1093/annonc/mdz127
doi: 10.1093/annonc/mdz127
pubmed: 31050707
pmcid: 6594457
Thouvenin J, Martínez Chanzá N, Alhalabi O, Lang H, Tannir NM, Barthélémy P, Malouf GG (2021) Efficacy of immune checkpoint inhibitors in upper tract urothelial carcinomas: current knowledge and future directions. Cancers (Basel) 13(17):4341. https://doi.org/10.3390/cancers13174341
doi: 10.3390/cancers13174341
pubmed: 34503152
Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S et al (2016) RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 62:132–7
doi: 10.1016/j.ejca.2016.03.081
pubmed: 27189322
pmcid: 5737828
Moss TJ, Qi Y, Xi L, Peng B, Kim TB, Ezzedine NE, Mosqueda ME, Guo CC, Czerniak BA, Ittmann M, Wheeler DA, Lerner SP, Matin SF (2017) Comprehensive genomic characterization of upper tract urothelial carcinoma. Eur Urol 72(4):641–649. https://doi.org/10.1016/j.eururo.2017.05.048
doi: 10.1016/j.eururo.2017.05.048
pubmed: 28601352
van der Post RS, Kiemeney LA, Ligtenberg MJ, Witjes JA, Hulsbergen-van de Kaa CA, Bodmer D, Schaap L, Kets CM, van Krieken JH, Hoogerbrugge N (2010) Risk of urothelial bladder cancer in lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 47(7):464–70. https://doi.org/10.1136/jmg.2010.076992
doi: 10.1136/jmg.2010.076992
pubmed: 20591884
Rao A, McGrath JE, Xiu J, de Souza AL, Gulati S, Abuali I, Sagaram S, Nabhan C, Korn WM, Ryan CJ et al (2021) Characterization of microsatellite instability (dMMR/MSI-H) and mutational landscape in a large contemporary cohort of upper tract urothelial cancer (UTUC) patients. J Clin Oncol 39:465
doi: 10.1200/JCO.2021.39.6_suppl.465
Andreev-Drakhlin A, Shah AY, Adriazola AC, Shaw L, Lopez L, James M, Matin SF, Alhalabi O, Gao J, Siefker-Radtke AO et al (2021) Efficacy of immune checkpoint blockade in patients with advanced upper tract urothelial cancer and mismatch repair deficiency or microsatellite instability (MSI). J Clin Oncol 39:487
doi: 10.1200/JCO.2021.39.6_suppl.487
O’Donnell PH, Balar AV, Castellano DE, De Wit R, Vaughn DJ, Powles T, Vuky J, Lee JL, Fradet Y, Bellmunt J, Fong L, Petrylak DP, Gerritsen WR, Quinn DI, Culine S, Bajorin DF, Jin Zhi X, Imai K, Moreno BH, Grivas P (2022) Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials. J Clin Oncol. https://doi.org/10.1200/JCO.2022.40.6_suppl.516
doi: 10.1200/JCO.2022.40.6_suppl.516
pubmed: 35658469
pmcid: 9937098
Esagian SM, Khaki AR, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Msaouel P, Koshkin VS, Grivas P (2021) Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU Int 128(2):196–205. https://doi.org/10.1111/bju.15324
doi: 10.1111/bju.15324
pubmed: 33556233
Taguchi S, Kawai T, Buti S, Bersanelli M, Uemura Y, Kishitani K, Miyakawa J, Sugimoto K, Nakamura Y, Niimi F, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H (2023) Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab. Immunotherapy. https://doi.org/10.2217/imt-2023-0028
doi: 10.2217/imt-2023-0028
pubmed: 37191002
Bersanelli M, Mazzaschi G, Giannatempo P, Raggi D, Farè E, Maruzzo M, Basso U, De Giorgi U, Vignani F, Banna GL, Stellato M, Tambaro R, Naglieri E, Losanno T, Procopio G, Pignata S, Necchi A, Buti S (2022) Immunotherapy and sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). Immunotherapy 14(2):107–114. https://doi.org/10.2217/imt-2021-0109
doi: 10.2217/imt-2021-0109
pubmed: 34784782
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390(10):875–88
doi: 10.1056/NEJMoa2312117
pubmed: 38446675
Aggen DH, Rosenberg JE (2024) Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma. Nat Rev Clin Oncol. https://doi.org/10.1038/s41571-024-00890-2
doi: 10.1038/s41571-024-00890-2
pubmed: 38622410